NS5a Replication Complex Inhibitor Will Be Used in Future Studies
October 11, 2013
Medivir: Janssen Has Acquired an NS5a Replication Complex Inhibitor That Will Be Evaluated with Simeprevir in Future Clinical Development
STOCKHOLM, Sweden–(BUSINESS WIRE)–October 08, 2013–
Medivir AB (OMX: MVIR) announced that Janssen Pharmaceuticals, Inc. (Janssen) has acquired the investigational compound GSK2336805 (GSK805), an NS5a replication complex inhibitor in phase II development for the treatment of chronic hepatitis C. Janssen has acquired all rights to develop and commercialize GSK2336805 including in combination with other drugs. Janssen acquired the compound from an affiliate of GlaxoSmithKline plc, financial details of the agreement have not been disclosed.
Janssen plans to initiate phase II studies to evaluate the use of GSK805 in interferon-free combinations with simeprevir (TMC435) and TMC647055, Janssen’s non-nucleoside polymerase inhibitor, for the treatment of chronic hepatitis C in adult patients with compensated liver disease.
Continue reading this entire article:
3 Hep C Treatment Side Effects Aided by Probiotics
A New Combination of Hepatitis C Drugs Leading to High Remission Rates